Status:
TERMINATED
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Novartis
Conditions:
Urologic Neoplasms
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
Primary: To determine the duration of use of zoledronic acid in improving Bone mineral density in patients with prostate cancer who are on hormones intermittently. Secondary Objectives: To describe...
Eligibility Criteria
Inclusion
- Patients: Who are 18 years of age and older Who have histologically documented adenocarcinoma of prostate Who are currently receiving LHRH agonists KPS greater than 80%Life expectancy greater than 6 months Provide written consent pursuant to regulatory requirements prior to initiation of study procedure
Exclusion
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00226954
Start Date
March 1 2003
End Date
February 1 2009
Last Update
March 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305